Steven Nash
Kansas City, MONPI 1942259692
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Uromedica, Incorporated accounts for 96.7% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $126,649, 5.1 times the $24,801 reported in 2019.
Across 338 payments — averaging $1235.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Uromedica, Incorporated$404K
- Astellas Pharma US Inc$9K
- AbbVie$4K
- Arthrex$241
- Bayer$104
- Johnson & Johnson$75
- plus $328 from 11 others
What the payments were for
- Consulting fees$219,00052%
- Speaking & faculty fees$122,52329%
- Travel & lodging$71,39617%
- Food & beverage$4,5231%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Uromedica, Incorporated | 271 | $403,633 |
| Astellas Pharma US Inc | 31 | $8,992 |
| AbbVie(2 entities) | 8 | $4,132 |
| Arthrex | 4 | $241 |
| Bayer | 1 | $104 |
| Johnson & Johnson | 5 | $75 |
| Blue Earth Diagnostics | 2 | $42 |
| Endo Pharmaceuticals Inc. | 2 | $42 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 2 | $33 |
| Convatec Inc. | 2 | $32 |
| Edwards Lifesciences | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Pfizer | 2 | $23 |
| Boston Scientific | 1 | $22 |
| Aytu Biopharma, Inc. | 2 | $22 |
| 180 Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ProACT$385,397
- MYRBETRIQ$7,162
- ACT$5,247
- Lupron Depot$4,063
- Xofigo$104
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.